OVERALL SITUATION AND LEADERSHIP CHANGES

The pharmaceutical landscape in 2023/24 has been marked by significant legislative changes in Europe and the Inflation Reduction Act in the U.S.

In Italy, there is noticeable activity in leadership changes within healthcare companies. Family-owned businesses are increasingly entrusting management to external managers, recognizing the importance of expertise in corporate performance.

Conversely, the subsidiaries of international companies tend to promote internal managers, avoiding external hires.

NEW TRENDS

Emerging technologies, such as artificial intelligence, are influencing the strategies and processes of biopharmaceutical companies, both globally and in niche sectors.

With the introduction of Non-Compete Clauses, antitrust authorities in various countries in the U.S. and Europe have shown interest in the potential negative effects on wages.

“Quiet quitting” is a trend where employees work only according to contractual terms, avoiding overtime and additional responsibilities. “Quiet cutting” is the employers’ response, presenting employees with difficult choices, such as resignation or changes in job roles